Metraipolis › archive › dc_5974b2f95cbf

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration — Europe PMC PMID:40922455

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40922455
DOI
10.1111/aos.17590
License (as archived)
solo-consultazione
Archived
2026-11-10T01:51:33.344Z
SHA-256 of the archived text
b4b386ca6fbca700a40a924a587fa7d6cb67568266d7807ad598ac3df9e2b7e3
Stable URL of this page
https://metraipolis.com/documento/dc_5974b2f95cbf

How to cite

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration — Europe PMC PMID:40922455 — Europe PMC (en), https://europepmc.org/article/MED/40922455 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5974b2f95cbf (Metraipolis archive dc_5974b2f95cbf, sha256 b4b386ca6fbca700a40a924a587fa7d6cb67568266d7807ad598ac3df9e2b7e3)
BibTeX
@misc{dc5974b2f95cbf,
  title = {Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration — Europe PMC PMID:40922455},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40922455},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5974b2f95cbf; sha256 b4b386ca6fbca700a40a924a587fa7d6cb67568266d7807ad598ac3df9e2b7e3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40922455. Agents can read the archived copy with the MCP tool read_document.